Policy

Julie Reed Talks About How Savings Can Differ Between Patients, Health Plans

May 14th 2022

By Skylar Jeremias

Julie M. Reed, the executive director of the Biosimilars Forum, discusses how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.

Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics

May 14th 2022

By Skylar Jeremias

Article

Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.

New House Bill Could Expand User Fee Programs for Biosimilars

May 12th 2022

By Skylar Jeremias

Article

A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.

Health IT for Biosimilars Spotlight: Cardinal Health's Decision Pathway

May 10th 2022

By Skylar Jeremias

Video

Amy Valley, vice president of clinical strategy and technology solutions at Cardinal Health, details the company's Decision Pathway, a health information technology (IT) tool that can assist practices with prescribing patients the lowest-cost product, including biosimilars.

Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate

May 9th 2022

By Ivo Abraham, PhD

Article

Biosimilar manufacturers should consider working together to overcome some of the barriers that prevent biosimilars from entering the market and obtaining market share, according to Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board.

Given Public Concerns, Canadian Policy Makers Should Be Cautious When Making New Biosimilar Policies

May 5th 2022

By Skylar Jeremias

Article

A report on biosimilar uptake and existing policies signals that policy makers should proceed with caution when establishing new policies to boost biosimilar utilization and savings, as many patients and providers still have concerns on their usage.

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

May 4th 2022

By Mary Caffrey

Article

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.

Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions

May 4th 2022

By Skylar Jeremias

Video

The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.

Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed

May 1st 2022

By Skylar Jeremias

Video

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.

Dr Sarfaraz K. Niazi Claims Biosimilar Growth Signals Need for Greater Testing, Policy Reform

April 28th 2022

By Skylar Jeremias

Article

Now that the United States’ acceptance of biosimilars matches that in the European Union, developers should be encouraging changes to testing regulations to increase biosimilar accessibility, according to Sarfaraz K. Niazi, PhD, in his recent perspective paper.